Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 229 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 February 19, 2026 Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases August 26, 2019 Berry Recipes August 14, 2020 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... December 7, 2021 Load more HOT NEWS First immunotherapy approved for cervical cancer in England and Scotland FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... FDA Approves New and Updated Indications for Temozolomide Under Project Renewal EMA Recommends Extension of Indications for Crizotinib
